Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Godoy

Showing results (191-200 of 209) with videos related to

Pageof 21
Sort By:
Physics in Medicine and Biology|May 21, 2016
Characterizing proton-activated materials to develop PET-mediated proton range verification markersJongmin Cho, Geoffrey S Ibbott, Matthew D Kerr, et al.
Arquivos Brasileiros De Cardiologia|January 15, 2026
Comparison between Five Risk Scores in Patients with Acute Coronary Syndromes Undergoing Surgical Revascularization during the Index HospitalizationJosé C Nicolau, Roberto R C V Giraldez, Fabio B Jatene, et al.
Angewandte Chemie (International Ed. in English)|October 24, 2025
Targeting Aurora Kinases as Essential Cell-Cycle Regulators to Deliver Multi-Stage Antimalarials Against Plasmodium FalciparumHenrico Langeveld, Keletso Maepa, Marché Maree, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 14, 2017
High HCV subtype heterogeneity in a chronically infected general population revealed by high-resolution hepatitis C virus subtypingF Rodriguez-Frias, L Nieto-Aponte, J Gregori, et al.
Biorxiv : the Preprint Server for Biology|May 25, 2026
Potent reaction hijacking inhibitors of <i>Plasmodium falciparum</i> asparagine tRNA synthetaseXi Ye, Lisl Y Esherick, Nutpakal Ketprasit, et al.
Science Translational Medicine|October 19, 2022
The anticancer human mTOR inhibitor sapanisertib potently inhibits multiple <i>Plasmodium</i> kinases and life cycle stagesLauren B Arendse, James M Murithi, Tarrick Qahash, et al.
Journal of the American College of Cardiology|March 8, 2023
Randomized Trial of Anticoagulation Strategies for Noncritically Ill Patients Hospitalized With COVID-19Gregg W Stone, Michael E Farkouh, Anuradha Lala, et al.
Biorxiv : the Preprint Server for Biology|August 12, 2025
The Human Chk1 Inhibitor CHIR-124 Shows Multistage Activity Against <i>Plasmodium falciparum</i> via Dual Inhibition of <i>Pf</i>Ark1 and Hemozoin FormationKathryn J Wicht, John G Woodland, Larnelle F Garnie, et al.
Angewandte Chemie (International Ed. in English)|May 3, 2025
The ATM Kinase Inhibitor AZD0156 Is a Potent Inhibitor of Plasmodium Phosphatidylinositol 4-Kinase (PI4Kβ) and Is an Attractive Candidate for Medicinal Chemistry Optimization Against MalariaJohn G Woodland, Dina Coertzen, Kathryn J Wicht, et al.
ACS Chemical Biology|June 13, 2026
The Human Chk1 Inhibitor CHIR-124 Shows Multistage Activity against the Human Malaria Parasite <i>Plasmodium falciparum</i> via Polypharmacological Inhibition of <i>Pf</i>Ark1 and Hemozoin FormationKathryn J Wicht, John G Woodland, Larnelle F Garnie, et al.
Pageof 21

Showing results (191-200 of 209) with videos related to

Sort By:
Pageof 21
Physics in Medicine and Biology|May 21, 2016
Characterizing proton-activated materials to develop PET-mediated proton range verification markersJongmin Cho, Geoffrey S Ibbott, Matthew D Kerr, et al.
Arquivos Brasileiros De Cardiologia|January 15, 2026
Comparison between Five Risk Scores in Patients with Acute Coronary Syndromes Undergoing Surgical Revascularization during the Index HospitalizationJosé C Nicolau, Roberto R C V Giraldez, Fabio B Jatene, et al.
Angewandte Chemie (International Ed. in English)|October 24, 2025
Targeting Aurora Kinases as Essential Cell-Cycle Regulators to Deliver Multi-Stage Antimalarials Against Plasmodium FalciparumHenrico Langeveld, Keletso Maepa, Marché Maree, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 14, 2017
High HCV subtype heterogeneity in a chronically infected general population revealed by high-resolution hepatitis C virus subtypingF Rodriguez-Frias, L Nieto-Aponte, J Gregori, et al.
Biorxiv : the Preprint Server for Biology|May 25, 2026
Potent reaction hijacking inhibitors of <i>Plasmodium falciparum</i> asparagine tRNA synthetaseXi Ye, Lisl Y Esherick, Nutpakal Ketprasit, et al.
Science Translational Medicine|October 19, 2022
The anticancer human mTOR inhibitor sapanisertib potently inhibits multiple <i>Plasmodium</i> kinases and life cycle stagesLauren B Arendse, James M Murithi, Tarrick Qahash, et al.
Journal of the American College of Cardiology|March 8, 2023
Randomized Trial of Anticoagulation Strategies for Noncritically Ill Patients Hospitalized With COVID-19Gregg W Stone, Michael E Farkouh, Anuradha Lala, et al.
Biorxiv : the Preprint Server for Biology|August 12, 2025
The Human Chk1 Inhibitor CHIR-124 Shows Multistage Activity Against <i>Plasmodium falciparum</i> via Dual Inhibition of <i>Pf</i>Ark1 and Hemozoin FormationKathryn J Wicht, John G Woodland, Larnelle F Garnie, et al.
Angewandte Chemie (International Ed. in English)|May 3, 2025
The ATM Kinase Inhibitor AZD0156 Is a Potent Inhibitor of Plasmodium Phosphatidylinositol 4-Kinase (PI4Kβ) and Is an Attractive Candidate for Medicinal Chemistry Optimization Against MalariaJohn G Woodland, Dina Coertzen, Kathryn J Wicht, et al.
ACS Chemical Biology|June 13, 2026
The Human Chk1 Inhibitor CHIR-124 Shows Multistage Activity against the Human Malaria Parasite <i>Plasmodium falciparum</i> via Polypharmacological Inhibition of <i>Pf</i>Ark1 and Hemozoin FormationKathryn J Wicht, John G Woodland, Larnelle F Garnie, et al.
Pageof 21